Trial Profile
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Linrodostat (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Cervical cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Mar 2024 This trial has been completed in Italy, According to European Clinical Trials Database record.
- 30 Jun 2022 Status changed from active, no longer recruiting to completed.
- 03 Mar 2022 This trial has been completed in Poland (Date of the global end of the trial : 15-Oct-2021), according to European Clinical Trials Database record.